Opinion on Drug Delivery in Asia-Pacific

Published within

« | 1 | 2 | 3 | » »|

Type Product title / description Pub Price
Expert View
Expert View

AstraZeneca and Boehringer Ingelheim steal limelight at European Society of Cardiology meeting

Well crafted, positive results for AstraZeneca's Brilinta and an unexpected coup for Boehringer Ingelheim's Pradaxa dominated the headlines following this year's European Society of Cardiology's Annual Meeting in Barcelona. Both announcements have a number of important implications for the wider cardiology market, from both therapeutic and commercial perspectives.

Published By Datamonitor
03 Sep 2009
Expert View
Expert View

Battle for HIV drug market share getting fiercer

The HIV market, worth $9.3 billion in 2007, is expected to grow to $15.1 billion by 2017, driven by the increasing prevalence of HIV worldwide and the longer life expectancy of patients receiving treatment. Despite this growth, the competition is getting tougher across all antiretroviral drug classes, which may cause some of the big players in the HIV market to opt out or be squeezed out.

Published By Datamonitor
24 Sep 2008
ResearchWire
ResearchWire

Biologics: a growing but threatened market

Published By Datamonitor
30 Jun 2006
CommentWire
CommentWire

BMS: combination pill rejection is yet another setback

Although this decision is unlikely to have a significant impact on Pravachol sales, it's still disappointing for BMS. It needs any revenue boost it can get this year, as sales of many of its other blockbuster drugs plummet. The FDA decision may also affect other players that plan to market single pills containing compounds for different indications, including Pfizer.

Published By Datamonitor
23 Jan 2002
Expert View
Expert View

Can biologic drugs tackle antibiotic resistance?

Antibody-based products present a novel approach to the treatment and prevention of infections, as an alternative to conventional antibiotics. Several companies are developing such agents for a range of indications, but their cost, complex manufacturing methods and mode of administration are restrictive. A high unmet need and well defined target groups are key to commercial success in this market.

Published By Datamonitor
30 Apr 2008
CommentWire
CommentWire

Cipla: lobbying for more generics in South Africa

Generics maker Cipla is trying to cut a deal to supply South African mining firm Anglo American with HIV drugs. Employer provision of HIV medicine is gaining popularity in South Africa, and last year's court case created the opportunity for the government to license generic versions of patented drugs. However, it has so far been reluctant to use this power.

Published By Datamonitor
20 Aug 2002
Expert View
Expert View

Directed molecular evolution: lifecycle management for biologics

Although biologics have an extremely attractive growth rate profile compared to small molecules, the rapid market expansion expected to occur between 2005 and 2010 will not continue at the same rate, due in part to the emergence of biosimilars. Thus, biologics manufacturers need to look at optimizing the lifecycle of their products through directed molecular evolution.

Published By Datamonitor
02 Aug 2006
Expert View
Expert View

Diverse challenges await generics industry

Because of the ever-increasing costs of healthcare provision the world over, many governments are enacting legislation to promote generic prescription in order to keep costs down. With drugs worth $160 billion in sales coming off patent by 2015, it would seem a good time to be in the generics industry. However the generics market is not without challenges.

Published By Datamonitor
07 Jul 2006
CommentWire
CommentWire

Faulding's folding: a generic expansion opportunity

Published By Datamonitor
18 Jul 2001
CommentWire
CommentWire

Flu remedies: out in the cold

Published By Datamonitor
08 Nov 2000

« | 1 | 2 | 3 | » »|

No help is available.